13856 research outputs found
Sort by
Gamma-polyglutamic acid-based intraocular irrigation solutions
No full text[[abstract]]Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) γ-polyglutamic acid (γ-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution, and b) an ophthalmically acceptable aqueous vehicle for the γ-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising γ-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient
細胞內藥物釋放的組合物及方法
No full text[[abstract]]本发明提供细胞内药物释放的组合物及方 法。该方法包括：(a) 提供一组合物，其包括一治 疗有效量的药剂，该药剂吸附于具有疏水性表面 的中孔径羟基磷灰石 (HAP) 上；(b) 将该组合物 暴露至一细胞；(c) 使该中孔径羟基磷灰石进入 该细胞中并于该细胞的溶酶体中降解，而使该药 剂自该中孔径羟基磷灰石脱附；(d) 使该经脱附 的药剂由该溶酶体释出至该细胞的细胞质中；以 及 (e) 使该经脱附的药剂释出至细胞外。该组合 物包括 (a) 具疏水性表面的中孔径羟基磷灰石 (HAP)；(b) 一治疗有效量的药剂，其吸附于该中 孔径羟基磷灰石的疏水性表面上。该组合物的特 征为：于体内持续释放该药剂达至少 4周
[[alternative]]Device for target particle transferring and the method thereof
No full text[[abstract]]本發明係揭露一種轉移標的粒子之裝置，其係包含一基板、一刻痕結構 及一標的基板部；其中，該基板之厚度為T且寬度為W，該基板包含一頂部及一底部，該頂部包括一頂部表面且該底部包括一底部表面；該刻痕結構係形成於該基板之該底部，且更包含寬度為W1之一溝槽，該溝槽係從該底部向該頂部延伸並位於距離該頂部表面t之處；該標的基板部之寬度為W2且厚度為T，其係位於該基板之該頂部及該底部之內，且其周圍環繞該溝槽；此外，本發明亦揭露以前述之裝置將一標的粒子從一裝置轉移到另一裝置之方法
Mesoporous silica nanoparticles for oil absorption
No full text[[abstract]]A method for prevention and/or treatment of steatorrhea in a subject is disclosed. The method comprises administering to the subject a composition comprising mesoporous silica nanoparticles (MSNs) in an amount effective for prevention and/or treatment of steatorrhea in the subjec
Precision control of large-scale green synthesis of biodegradable gold nanodandelions as potential radiotheranostics
No full text[[abstract]]The present invention relates to a new type of metabolizable flower-like gold nanodandelion (GND), which possesses features: (1) large scale green synthesis with high monodispersity and a circa 100% yield; (2) cellular/physiological degradability; (3) precision control of the shape, petal number and size; (4) highly efficient radiotheranostics encompassing better enhanced CT contrast and pronounced x-ray induced ROS generation than conventional spherical AuNP
Method and composition for decreasing the pschotomimetic and addictive disorder of ketamine
No full text[[abstract]]The present invention relates to a method for decreasing the psychotomimetic side effects and enhancing the antidepressant-like effects of ketamine by the combination of ketamine with a methylglycine derivative. The present invention also relates to a method for depression treatment comprising administrating ketamine combined with a methylglycine derivative. The present invention further provides a method for preventing or treating addictive disorders of ketamine by administrating a methylglycine derivative
Anti-abeta antibodies and uses thereof
No full text[[abstract]]An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14; a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15; a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24; a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25; a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26; and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to Αβ1-42 or an N-terminal modified form thereof
Heterocyclic compounds and their application
No full text[[abstract]]FIELD: medicine; pharmaceutics.SUBSTANCE: invention relates to heterocyclic compounds of the formula (I), where R1and R2are independently H, NH2or C1-6alkyl, or R1and R2, together with two carbon atoms with which they are bound, are phenyl or heteroaryl selected from thienyl, imidazolyl and pyridyl; each of R3and R4is independently, or, which are such as disclosed in the claims; R5is H; R6is absent or is H; R7is C3-10cycloalkyl. The invention also relates to a pharmaceutical composition containing a compound of the formula (I), to a method for mobilizing hematopoietic stem cells (HSC) and endothelial progenitor cells (EPC) into peripheral blood circulation and to a method for treating hepatocellular carcinoma, renal damage, myocardial infarction, or mild traumatic brain injury.EFFECT: technical result is compounds of the formula (I) used to disrupt the interaction between CXCR4 and CXCL12.(I)31 cl, 8 e
複素環式化合物及びその使用
No full text[[abstract]]Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation, and for treating tissue injury, cancer, inflammatory disease, and autoimmune disease
[[alternative]]Dipicolylamine derivatives and their pharmaceutical uses
No full text[[abstract]]화학식(I)의 디피콜릴아민 화합물이 본원에서 기재되어 있다. 금속 이온과 이들 화합물을 함유하는 약제학적 조성물이 또한 개시되어 있다. 인사이드-아웃 포스파티딜세린을 함유하는 세포와 연관된 병태를 이들 화합물로 치료하기 위한 방법이 추가로 개시되어 있다